Simple fluorinated moiety insertion on Aβ 16–23 peptide for stain-free TEM imaging by Sonzini, Silvia et al.
Analyst
PAPER
Cite this: Analyst, 2015, 140, 2735
Received 11th December 2014,
Accepted 29th January 2015
DOI: 10.1039/c4an02278e
www.rsc.org/analyst
Simple ﬂuorinated moiety insertion on Aβ 16–23
peptide for stain-free TEM imaging†
Silvia Sonzini, Samuel T. Jones, Zarah Walsh and Oren A. Scherman*
Peptide aggregation and ﬁbre formation are one of the major underlying causes of several neurodegen-
erative disorders such as Alzheimer’s disease. During the past decades the characterisation of these ﬁbres
has been widely studied in an attempt to further understand the nature of the related diseases and in an
eﬀort to develop treatments. Transmission electron microscopy (TEM) is one of the most commonly used
techniques to identify these ﬁbres, but requires the use of a radioactive staining agent. The procedure we
report overcomes this drawback through simple addition of a ﬂuorinated moiety to a short Amyloid β
sequence via solid phase peptide synthesis (SPPS). This method is synthetically straightforward, widely
applicable to diﬀerent aggregation-prone sequences and, above all, allows for stain-free TEM imaging
with improved quality compared to standard imaging procedures. The presence of the ﬂuorinated moiety
does not cause major changes in the ﬁbre structure or aggregation, but rather serves to dissipate the
microscope’s electron beam, thus allowing for high contrast and straightforward imaging by TEM.
1. Introduction
Several degenerative diseases, such as Alzheimer’s,1 Parkin-
son’s,2 Huntington’s disease3 and type II diabetes4 are related
to an accumulation of amyloid fibrils.5 The proteins compos-
ing these fibrils vary in each of the diﬀerent diseases, but
there are substantial similarities in their structural properties.
Protein functions are known to be closely related to their
three-dimensional structure, therefore the mechanisms of
pathogenesis in all these diseases show common features as
well.6,7 In particular, the structure of Amyloid β (Aβ) fibrils has
been studied with numerous techniques to capture as much
information as possible on their aggregation pathway and
further understand the development of the related disease.8–15
These fibrils have not only been investigated for their role in
Alzheimer’s disease, but they have also been gathering increas-
ing interest on account of their mechanical and adhesive pro-
perties and their natural propensity to self assemble.16–20
One of the more reliable and common methods to study
and characterise amyloid fibres, both from a biomedical and a
material point of view, is transmission electron microscopy
(TEM). Wild-type (WT) peptides are, however, diﬃcult to
image with electron microscopy as they do not eﬃciently dissi-
pate the beam current, resulting in imaging artefacts. The
standard procedure for TEM imaging, therefore, consists of
staining the fibres with a radioactive uranyl acetate solution,8
which allows the fibres to be imaged as the uranyl acetate
helps to dissipate the electron beam. This method, even if
widely applied, can be misleading since the microscope
images show only regions that interact with the staining solu-
tion and not necessarily the peptide itself. Building on pre-
vious work from our group21 we report, herein, the
incorporation of an N-terminal fluorinated moiety (F) via solid
phase peptide synthesis (SPPS) that allows stain-free TEM to
be performed on peptide fibres. Importantly, the incorporation
of this moiety does not interfere with the aggregation process
typical of the amyloid fragment Aβ (16–23). In our case only
the material (peptide) containing the fluorine moiety will be
seen in the TEM, since no additional staining technique is
applied (Fig. 1).
Fig. 1 Scheme of F-Aβ (16–23) synthesis and aggregation.
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c4an02278e
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Introducing fluorinated amino acids in peptides and pro-
teins is common practice in bioengineering.22,23 While fluo-
rine is isosteric with hydrogen, the C–F bond is stronger than
the C–H bond. Additionally, it is highly dipolar and relatively
non-polarisable, which generally helps increase the hydropho-
bicity but also contributes to fluorine behaving as a hydrogen-
bond acceptor; these features all generally improve protein
stability.24,25 Moreover, fluorine has a low natural abundance
in proteins and can therefore act as a tool for protein analysis
in several spectroscopic techniques, such as nuclear magnetic
resonance (19F-NMR)26 and positron emission topography
(18F-PET).27 Nevertheless, fluorine insertion into peptides has
never been applied as an imaging tool in TEM to the best of
our knowledge.
2. Experimental section
2.1. Materials
All amino acids used, O-(benzotriazol-1-yl)-N,N,N′,N′-tetra-
methyluronium hexafluorophosphate (HBTU), dichloro-
methane (DCM) and dimethyl formamide (DMF) were bought
from AGTC Bioproducts. NovaPEG Rink amide resin was pur-
chased from Merck Novabiochem. Diisopropylethylamine
(DIPEA), trifluoroacetic acid (TFA), 3,5-bis(trifluoromethyl)
benzoic acid, thioflavin T, monobasic potassium phosphate,
dibasic sodium phosphate, glutaraldehyde solution and uranyl
acetate dihydrate were purchased from Sigma-Aldrich. HPLC-
grade acetonitrile and N-methylpyrrolidone (NMP) and analyti-
cal grade purity 1,1,1,3,3,3,-hexafluoroisopropanol (HFIP),
piperidine and triisopropylsilane (TIS) were bought from
Fisher Scientific. The buﬀer used was a sterile filtered 10 mM
phosphate buﬀer adjusted to pH 7.4 prepared by dilution from
a stock solution of 0.5 M phosphate buﬀer pH 7.4 in ultrapure
water (Synergy UV Ultrapure water system).
2.2. Peptide preparation
Aβ (16–23) and F-Aβ (16–23) were prepared by SPPS (CEM
Liberty Automated Microwave Peptide Synthesiser), the N-
terminal coupling with 3,5-bis(trifluoromethyl)-benzoic acid
was performed manually under standard HBTU coupling con-
ditions allowing 12 h for the reaction to occur. The peptides
were purified by high-performance liquid chromatography
(HPLC), using an Agilent 1300, an Agilent Zorbax C18 column
and a water–acetonitrile gradient with 0.1% TFA. The gradient
ranged from 90 : 10 to 10 : 90 water–acetonitrile over 25 min
and it was preceded by a pre-run of 2 min at 90 : 10 water–
acetonitrile for a total run time of 27 min. The final purity was
assessed by analytical HPLC (Varian 940-LC system, Agilent
Eclipse Plus C18 column and the same water–acetonitrile gra-
dient) and electrospray ionisation mass spectrometry (Thermo
Scientific LTQ Orbitrap Velos mass spectrometer) and found to
be ≥95% (see ESI†). Fluorine presence in F-Aβ (16–23) was also
measured by 19F-NMR (Bruker DPX 400 MHz spectrometer)
(see ESI†). After purification, the peptides were lyophilised and
stored at −20 °C.
Unless otherwise stated, Aβ (16–23) and F-Aβ (16–23)
samples were treated, as follows, prior to each experiment. The
peptides were disaggregated by dissolution in TFA at a concen-
tration of 1 mg ml−1, sonicated for 30 s, evaporated to a dry
film, redissolved in HFIP and aliquoted; the solvent was then
evaporated to dryness as described previously.28 Dry peptide
films can be stored at –20 °C until used, but they were usually
freshly prepared.
2.3. Circular dichroism (CD) measurements
CD data were recorded on an Applied Photophysics Chirascan
spectrometer, measuring from 250 nm to 195 nm at 25 °C. Aβ
(16–23) and F-Aβ (16–23) pretreated samples were dissolved
(50 μM) in phosphate buﬀer 10 mM pH 7.4, the concentration
checked via UV-vis spectroscopy (see ESI†), and the first data
point (time 0 h) collected. The samples were then constantly
shaken in an incubator (INFORS HT Multi-tiron II) at 37 °C
and 250 rpm and data acquired every 12 h to a total of ∼36 h
incubation. Each peptide was analysed as three independent
samples and the data averaged.
2.4. Thioflavin T (ThT) assay
The assay was performed by recording ThT emission with a
Cary Eclipse fluorimeter. The excitation was applied at 452 nm
and the emission collected at 490 nm, the temperature was
kept at 25 °C. Aβ (16–23) and F-Aβ (16–23) samples were pre-
pared as for the CD analyses. For each data point 50 μl aliquot
of each aggregation solution was added to 750 μl of freshly fil-
tered ThT solution (100 μM in phosphate buﬀer 10 mM pH
7.4) and the emission collected. The samples were then aggre-
gated in the same conditions used for the CD analyses and
data points acquired at several time intervals to a total of
∼72 h incubation. The data are reported as mean ± STD of
three independent samples.
2.5. TEM imaging
TEM images were recorded using a FEI Philips Tecnai 20 trans-
mission electron microscope. Aβ (16–23) and F-Aβ (16–23)
samples stored as dry-film were dissolved at a concentration of
0.5 mg ml−1 in phosphate buﬀer 10 mM pH 7.4 and shaken in
an incubator (INFORS HT Multi-tiron II) at 37 °C and 250 rpm
for two weeks to allow the fibrillation process to occur.
Samples were prepared as previously reported8 on Lacey®
Carbon (400 mesh) Cu grids (Agar Scientific) fixing the
samples with 2.5% glutaraldehyde solution in water.
2.6. Atomic and electrostatic force microscopy (AFM, EFM)
10 μl of Aβ (16–23) and F-Aβ (16–23) as prepared for the TEM
measurements were diluted in 990 μl of ultrapure water. The
solution was shaken to ensure mixing and drop cast onto
highly ordered pyrolytic graphite (HOPG) approximately 1 cm ×
1 cm with a roughness of 1 nm (Elektron Technologies, Essex,
UK). The HOPG had been previously cleaved in order to
remove any extraneous organic matter. Solutions of both Aβ
(16–23) and F-Aβ (16–23) were allowed to remain on the freshly
cleaved surfaces for 2 min before removing the peptide
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solution by pipetting and then drying with N2. Topography
and electrostatic force images were taken independently on an
Agilent 5500 AFM (Santa Clara, CA, USA) in alternating current
(ACAFM) and electrostatic force microscopy (EFM) modes. For
ACAFM mode, SiN3 OTESPA cantilevers with a resonant fre-
quency of approx. 330 kHz and tip radius of 7 nm were used
while EFM was conducted with SPM-PIT Pt-Ir coated SiN3 con-
ductive probes with a resonant frequency of 63.9 kHz and tip
radius of 20 nm. Both cantilevers were purchased from Bruker
Nano AXS (France). Performing the measurements indepen-
dently allowed higher resolution topological images in order
to better study morphological changes induced by the inser-
tion of the fluorinated moiety. Samples were grounded for
EFM measurements using silver wire. Images were taken over
an area of approximately 5 μm2 at a rate of 1.02 lines s−1 with a
resolution of 256 × 256 or 1024 × 1024 pixels. During measure-
ments the topographic trace in both trace and retrace mode,
amplitude, phase, EFM X component and EFM phase were all
recorded.
3. Results and discussion
Aβ (16–23) is a short peptide, 8 residues long, derived from the
Aβ (1–40/42) hairpin. This sequence bears in position 19 and
20 (numbered from the original Aβ (1–40/42) peptide) two Phe
residues, which confer a hydrophobic character and render
this peptide aggregation prone. On the other hand, the lower
molecular weight of this sequence, compared with the full
length Aβ (1–40/42), gives rise to a slower rate of fibrillation
and higher solubility in buﬀer solutions. Aβ (16–23) has been
referred to as the core structure causing fibrillation of Aβ WT;
its aggregation pathway and interactions with the full length
sequence have therefore been widely studied.29–32 All these
characteristics make Aβ (16–23) a good candidate to study the
eﬀect of a small fluorinated moiety on the timescale and
aggregation morphology.
The fluorinated moiety F, 3,5-bis-(trifluoromethyl)-benzoic
acid, was attached at the N-terminal amine through a standard
SPPS procedure. The reaction resulted in a high yield and no
side products were encountered during the cleavage procedure.
This method, introducing some additional orthogonal protec-
tive group during the SPPS, can be easily applied on any free
amine on a sequence. Aβ (16–23) and F-Aβ (16–23) fibre for-
mation was thus studied through the same techniques and the
results obtained compared to evaluate any diﬀerences.
A common method to study the timescale of amyloid
peptide aggregation is CD.33,34 The change in secondary struc-
ture from a disordered to a defined conformation of the
peptide backbone such as α-helix or β-sheet can be readily
observed in CD spectra. We, therefore, studied the secondary
structure changes of Aβ (16–23) and F-Aβ (16–23) to compare
their aggregation, as reported in Fig. 2. Up to 12 h of incu-
bation at 37 °C both peptides mainly showed a disordered con-
formation, characterised by a low intensity signal and a
negative broad peak at 195–200 nm. Spectra taken after 24 h of
incubation indicated some extent of aggregation, but it was
only after 36 h that both samples showed a β-sheet structure
characterised by a positive peak at 205 nm and a negative peak
around 230 nm. CD spectra of peptides in a β-sheet confor-
mation are usually reported with a positive peak at 198 nm
and a negative peak at 215 nm, however, sequences containing
several Phe residues in close proximity can induce a shift of
10–15 nm each caused by n–π* interactions between the
phenyl side chains, as we observe in this case.34–36 The fluori-
nated peptide (Fig. 2B) still shows a shoulder peak at 215 nm,
indicative of a β-sheet configuration, which might be related to
some structural features added by the presence of an
additional aromatic ring, far from the two Phe side chains,
and thus less involved in any n–π* interactions. The overall CD
spectra suggest, nevertheless, that the aggregation propensity
of F-Aβ (16–23) is not drastically changed from that of the WT
and the rate of the aggregation process is very similar. To
support the CD data, we also analysed the aggregation profile
for both Aβ (16–23) and F-Aβ (16–23) using the ThT assay. ThT
is a low fluorescent molecule whose emission is enhanced
upon interaction with hydrophobic pockets, specifically it is
usually applied to monitor β-sheet formation in amyloidogenic
sequences.28 In Fig. 3 is possible to compare the data for both
Aβ (16–23) and F-Aβ (16–23) over a time of 72 h. Both of the
sequences showed a lag phase for the first ∼20 h, where the
Fig. 2 CD spectra of (A) Aβ (16–23) and (B) F-Aβ (16–23), 50 μM in
10 mM phosphate buﬀer at pH 7.4.
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curve was almost flat, than an elongation step between 23 h
and 35 h and, finally, a steady phase after ∼40 h, where ThT
emission did not increase anymore. Therefore, both Aβ (16–23)
and F-Aβ (16–23) not only presented a similar aggregation
profile via ThT assay, but these data were also in good agree-
ment with the aggregation timescale obtained by CD analyses
(Fig. 2). On the basis of these results it is reasonable to con-
clude that no dramatic changes to the aggregation process
should occur when such a small molecule is added at the N-
terminus of longer sequences such as Aβ (1–40/42).
To confirm the similarity in the aggregation behaviour of
the fluorinated peptide compared to the WT indicated by CD
measurements and ThT assay, two fibres solutions (one for
each peptide) were drop cast onto HOPG substrates and
imaged using ACAFM. Fig. 4A and B show representative
images for the Aβ (16–23) (Fig. 4A) and the F-Aβ (16–23)
(Fig. 4B) fibrils. Comparing the images it is clear that no sig-
nificant diﬀerences in morphology are present between the
WT and the fluorinated peptide fibres. All fibres are in the
region of 10–15 nm wide, 1–2 nm high and several hundred
nanometers in length, although some exceptionally long WT
fibres were detected (longer than 1 μm) as shown in Fig Aβ
(16–23) and (B) F-Aβ (16–23).
This fibre is of particular interest as, after detailed analysis
of its height, cross-over of the fibril is readily evident (see
Fig. S6 in ESI†).
After verifying the consistency of aggregation behaviour
between the fluorinated and the WT peptide with CD, ThT
assay and ACAFM, we proceeded with TEM measurements.
Our aim was not only to further analyse the morphology of the
fibres originating from both the peptides, but also investigate
the ability of the fluorinated moiety to dissipate the beam
current, allowing the sample to be imaged without any
additional staining. As mentioned previously, the reported pro-
cedure to prepare peptides and protein samples for TEM ana-
lyses is based on staining the deposits on the grid with a
radioactive solution of uranyl acetate. This methodology bears
two major drawbacks: the hazard due to the use of a radio-
active compound and the need for a conductive material,
which is not an integral part of the structure of interest.
The use of the fluorinated moiety F allowed us to address
both of these issues. Fig. 5 shows the TEM images of both Aβ
(16–23) and F-Aβ (16–23). Aβ (16–23) samples were stained fol-
lowing the common uranyl acetate protocol,8 while F-Aβ
(16–23) samples were only treated with an immobilising agent,
to prevent any degradation of the sample, but without any
additional staining applied.
Significantly-improved images of the amyloid fibres were
obtained when the fluorinated moiety F was included in the
peptide strand compared to the WT fibres. Both the contrast
and the resolution are greatly enhanced, the cross-over of the
fibres is clearly visible and, above all, only the fibre-peptide
Fig. 3 ThT assay of Aβ (16–23) and F-Aβ (16–23), 50 μM in 10 mM phos-
phate buﬀer at pH 7.4 diluted 16-fold in fresh ﬁltered ThT solution
(100 μM in phosphate buﬀer 10 mM pH 7.4). The data reported are the
mean ± STD of three independent samples for each peptide.
Fig. 5 TEM images of the ﬁbres of (A) Aβ (16–23) sample stained with
uranyl acetate 2% solution, (B) Aβ (16–23) sample without any type of
staining (barely visible), (C) F-Aβ (16–23) sample, presenting particularly
regular cross-over and (D) F-Aβ (16–23), reporting some cross-over
measurements in the inset. Peptides were 0.5 mg ml−1 solutions in
phosphate buﬀer pH 7.4, the images were taken after 2 weeks of incu-
bation at 37 °C. F-Aβ (16–23) was always imaged without any additional
staining.
Fig. 4 AFM images of (A) Aβ (16–23) and (B) F-Aβ (16–23), 0.5 mg ml−1
in 10 mM phosphate buﬀer at pH 7.4 diluted 100-fold in ultrapure water
cast and imaged on HOPG.
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itself is visible (Fig. 5C, D and S5 in ESI†). In addition to these
advantages, the morphology of the fibres obtained both from
Aβ (16–23) and F-Aβ (16–23) aggregation was very similar and
in line with amyloid fibres previously reported in the litera-
ture.31,37,38 Moreover, the data obtained from TEM analyses
are in close agreement with the AFM results previously men-
tioned in this section. The width of the fibres is between
10–25 nm in both of the peptides; thinner fibres (filaments)
present a width around 8–13 nm, while wider fibres, up to
22 nm in F-Aβ (16–23) and 28 nm in Aβ (16–23), are probably
more mature fibrils. The length of the fibres vary significantly
for both peptides, they are usually a few 100 nm long, but
some of the longest fibres reach 1 μm. Cross-overs are visible
for some of the fluorinated fibres and spacing between such
points range between 150–200 nm, which is in agreement with
what has been previously reported in the literature for WT Aβ
(1–40/42).39,40 Taken together such evidence is very supportive
of significantly improving standard TEM imaging of peptides,
by the sole incorporation of a small fluorinated moiety,
without interfering in the natural aggregation pathway.
In an eﬀort to explain why the F-Aβ (16–23) dissipates the
beam current more eﬀectively in the TEM than either the
unstained or uranyl acetate stained Aβ (16–23), we studied the
variations in the charge transport properties of F-Aβ (16–23)
fibres compared to those of the WT. Examination of the F-Aβ
(16–23) and Aβ (16–23) fibres were carried out using EFM
(Fig. 6B, D and S7–8 in ESI†). This technique allows the long
range electrostatic forces of the material, rather than the short
range van der Waals forces in conventional AFM, to be imaged
supplying qualitative information of the surface electrical pro-
perties. The results of these experiments, shown in Fig. 6, indi-
cate an increase in electrostatic force of the F-Aβ (16–23) over
the Aβ (16–23) fibres. Fig. 6A, C show the lower resolution
topographical images obtained during EFM measurements of
the WT and the fluorinated peptide, respectively. These exper-
iments verify the presence of fibres at the imaging location.
Using the electrostatic force of the highly conductive HOPG as
the relative standard, the diﬀerence in the electrostatic force of
the peptide fibres can be estimated. Looking first at Fig. 6B,
the presence of the Aβ 16–23 fibres is quite evident as the long
range electrostatic forces of the fibres are significantly weaker
than the HOPG background, thus a decrease in the signal is
evident where the fibres are located. Comparing this with
Fig. 6D, here the distinction between the HOPG substrate and
the fluorinated peptide is much less clear, referring particu-
larly to the fibres visible in the right hand side of Fig. 6C. This
indicates an increase in the electrostatic forces of the fibres,
becoming relatively closer to the signal of the HOPG and thus
more diﬃcult to distinguish. In the case of the larger fibre
there seems to be a change in the distribution of the electro-
static force along the length of the fibre potentially indicating
a diﬀerence in distribution of the conducting moiety or a
cross-over point in the fibril. This result can explain the
peculiar behaviour of F-Aβ (16–23) in the TEM analysis, but it
also indicates that simple addition of a fluorinated moiety on
an aggregation prone peptide is an eﬀective way to increase
charge transport in the fibres.
4. Conclusions
A simple synthetic modification on a short amyloidogenic
peptide, the 16–23 fragment of Aβ, enabled the recording of
TEM images without any further staining procedures. It has
been shown, through independent techniques, that the fluori-
nated moiety inserted at the end of the peptide sequence does
not significantly change the aggregation time or the mor-
phology of the fibres, thus suggesting the use of this molecule
for imaging of longer and more biologically-relevant peptides,
such as the parent Aβ (1–40/42). The ability of F-Aβ (16–23) to
dissipate the beam and thus be imaged in the TEM has been
supported by a change in conductivity from the WT peptide to
the fluorinated variant, which has been quantified by EFM
measurements. These preliminary results pave the way to
further studies on fibrillogenic peptides by insertion of several
fluorinated residues and possible new applications of fluorine
in protein stability and conformational studies.
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